Granules India, after market hours, said the US Food and Drug Administration had concluded its inspection at the company’s Gagillapur unit in Telangana last week and did not make any observations on the facility. The unit manufactures pharmaceutical formulation ingredients and finished dosages. The inspection took place in the wake of the filing of an ANDA from the unit. Shares could react positively to the development.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.